Cargando…

A Comment on the Post-Finasteride Syndrome

The post-Finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat hair loss or benign prostatic hyperplasia. While the incidence of persistent sexual, mental, and physical side effects despite quitting finasteride is unknown, and the condition is not recog...

Descripción completa

Detalles Bibliográficos
Autores principales: Rezende, Hudson Dutra, Dias, Maria Fernanda Reis Gavazzoni, Trüeb, Ralph Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369643/
https://www.ncbi.nlm.nih.gov/pubmed/30783332
http://dx.doi.org/10.4103/ijt.ijt_61_18
_version_ 1783394227261014016
author Rezende, Hudson Dutra
Dias, Maria Fernanda Reis Gavazzoni
Trüeb, Ralph Michel
author_facet Rezende, Hudson Dutra
Dias, Maria Fernanda Reis Gavazzoni
Trüeb, Ralph Michel
author_sort Rezende, Hudson Dutra
collection PubMed
description The post-Finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat hair loss or benign prostatic hyperplasia. While the incidence of persistent sexual, mental, and physical side effects despite quitting finasteride is unknown, and the condition is not recognized by the scientific community, individuals who suffer from PFS do present with very distinctive and homogenous symptoms. The concept has emerged from reports of nondermatologists, neuroendocrinological research, case reports, and uncontrolled studies. These have been scrutinized by hair experts who found that persistent sexual side effects were only documented in low-quality studies with a strong bias selection and a significant nocebo effect. Others totally dispute the credibility of the PFS. In any case, the PFS is a problem that has to be dealt with. Low-quality studies neither confirm nor refute the condition as a valid nosologic entity. Therefore, it is as inappropriate to dismiss the condition, as it would be to demonize finasteride for the treatment of male pattern hair loss. Whether the PFS represents a nocebo reaction or a real drug adverse event is irrelevant, while the best way to alleviate the emotional distress related to hair loss is to effectively treat the condition causing the problem. It is not sufficient to only discuss the plausibility of the PFS. There is a need for practical recommendations to include such important issues as patient selection and risk assessment, appropriate patient information, how to react in case of drug-related adverse events, issues of fertility and malignancy, management of the PFS, and alternatives, specifically the use of topical finasteride. It is the aim of this commentary to provide the respective information.
format Online
Article
Text
id pubmed-6369643
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-63696432019-02-19 A Comment on the Post-Finasteride Syndrome Rezende, Hudson Dutra Dias, Maria Fernanda Reis Gavazzoni Trüeb, Ralph Michel Int J Trichology Commentary The post-Finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat hair loss or benign prostatic hyperplasia. While the incidence of persistent sexual, mental, and physical side effects despite quitting finasteride is unknown, and the condition is not recognized by the scientific community, individuals who suffer from PFS do present with very distinctive and homogenous symptoms. The concept has emerged from reports of nondermatologists, neuroendocrinological research, case reports, and uncontrolled studies. These have been scrutinized by hair experts who found that persistent sexual side effects were only documented in low-quality studies with a strong bias selection and a significant nocebo effect. Others totally dispute the credibility of the PFS. In any case, the PFS is a problem that has to be dealt with. Low-quality studies neither confirm nor refute the condition as a valid nosologic entity. Therefore, it is as inappropriate to dismiss the condition, as it would be to demonize finasteride for the treatment of male pattern hair loss. Whether the PFS represents a nocebo reaction or a real drug adverse event is irrelevant, while the best way to alleviate the emotional distress related to hair loss is to effectively treat the condition causing the problem. It is not sufficient to only discuss the plausibility of the PFS. There is a need for practical recommendations to include such important issues as patient selection and risk assessment, appropriate patient information, how to react in case of drug-related adverse events, issues of fertility and malignancy, management of the PFS, and alternatives, specifically the use of topical finasteride. It is the aim of this commentary to provide the respective information. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6369643/ /pubmed/30783332 http://dx.doi.org/10.4103/ijt.ijt_61_18 Text en Copyright: © 2019 International Journal of Trichology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Commentary
Rezende, Hudson Dutra
Dias, Maria Fernanda Reis Gavazzoni
Trüeb, Ralph Michel
A Comment on the Post-Finasteride Syndrome
title A Comment on the Post-Finasteride Syndrome
title_full A Comment on the Post-Finasteride Syndrome
title_fullStr A Comment on the Post-Finasteride Syndrome
title_full_unstemmed A Comment on the Post-Finasteride Syndrome
title_short A Comment on the Post-Finasteride Syndrome
title_sort comment on the post-finasteride syndrome
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369643/
https://www.ncbi.nlm.nih.gov/pubmed/30783332
http://dx.doi.org/10.4103/ijt.ijt_61_18
work_keys_str_mv AT rezendehudsondutra acommentonthepostfinasteridesyndrome
AT diasmariafernandareisgavazzoni acommentonthepostfinasteridesyndrome
AT truebralphmichel acommentonthepostfinasteridesyndrome
AT rezendehudsondutra commentonthepostfinasteridesyndrome
AT diasmariafernandareisgavazzoni commentonthepostfinasteridesyndrome
AT truebralphmichel commentonthepostfinasteridesyndrome